Carlino, F.;                     Diana, A.;                     Ventriglia, A.;                     Piccolo, A.;                     Mocerino, C.;                     Riccardi, F.;                     Bilancia, D.;                     Giotta, F.;                     Antoniol, G.;                     Famiglietti, V.;     
    et al.    HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study. Cancers 2022, 14, 4981.
    https://doi.org/10.3390/cancers14204981
    AMA Style
    
                                Carlino F,                                 Diana A,                                 Ventriglia A,                                 Piccolo A,                                 Mocerino C,                                 Riccardi F,                                 Bilancia D,                                 Giotta F,                                 Antoniol G,                                 Famiglietti V,         
        et al.        HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study. Cancers. 2022; 14(20):4981.
        https://doi.org/10.3390/cancers14204981
    
    Chicago/Turabian Style
    
                                Carlino, Francesca,                                 Anna Diana,                                 Anna Ventriglia,                                 Antonio Piccolo,                                 Carmela Mocerino,                                 Ferdinando Riccardi,                                 Domenico Bilancia,                                 Francesco Giotta,                                 Giulio Antoniol,                                 Vincenzo Famiglietti,         
         and et al.        2022. "HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study" Cancers 14, no. 20: 4981.
        https://doi.org/10.3390/cancers14204981
    
    APA Style
    
                                Carlino, F.,                                 Diana, A.,                                 Ventriglia, A.,                                 Piccolo, A.,                                 Mocerino, C.,                                 Riccardi, F.,                                 Bilancia, D.,                                 Giotta, F.,                                 Antoniol, G.,                                 Famiglietti, V.,                                 Feliciano, S.,                                 Cangiano, R.,                                 Lobianco, L.,                                 Pellegrino, B.,                                 De Vita, F.,                                 Ciardiello, F.,                                 & Orditura, M.        
        
        (2022). HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study. Cancers, 14(20), 4981.
        https://doi.org/10.3390/cancers14204981